

Date Mailed: November 17, 2003

Sheet 1 of 4

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 1199L21USC2	Application Number: NEW FILING
	Applicant: ALFERNES ET AL.	
	Filing Date: HERewith	Group Art Unit: UNKNOWN

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
NV	3,983,863	10/1976	Jankov et al.			
	4,048,990	09/1977	Goetz			
	4,428,375	01/1984	Ellyson			
	4,630,597	12/1986	Kantrowitz et al.			
	4,690,134	09/1987	Soyden			
	4,821,723	04/1989	Baker, Jr. et al.			
	4,878,890	11/1989	Bilwels			
	4,936,857	06/1990	Kullik			
	4,957,477	09/1990	Lundback			
	4,973,300	11/1990	Wright			
NV	4,976,730	12/1990	Kwan-Gott			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
NV	295 17 393 U 1	03/1996	DE			x	
	0 280 564 A2	08/1988	EP				
	60-203250 A2	10/1985	JP				x
NV	01-145066 A	06/1989	JP			Abstract	

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)		
		"Supplement to Circulation", Abstracts from the 68th Scientific Sessions, Vol. 92, No. 6, 3 pages (October 15, 1996).
NV		Capomolla, S. et al., "Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: Hemodynamic improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function", <i>American Heart Journal</i> , pp. 1089-1098 (December 1997).
		Capouna, E. et al., "Girdling Effect of Nonstimulated Cardiomyoplasty on Left Ventricular Function", <i>Ann. Thorac Surg.</i> , Vol. 56, pp. 867-871 (1993).
NV		Cohn, J., "The Management of Chronic Heart Failure", <i>The New England Journal of Medicine</i> , Vol. 335, No. 7, pp. 490-498 (August 15, 1996).

34379

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED 07/16/04
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement (Form (PTO-1449))

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Date Mailed: November 17, 2003


Sheet 2 of 4

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11998.21 USC2	Application Number: NEW FILING
	Applicant: ALPERNESS ET AL.	
	Filing Date: HEREWITH	Group Art Units: UNKNOWN

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
NV	5,057,117	10/1991	Atweh			
	5,087,243	02/1992	Avitall			
	5,131,905	07/1992	Grooters			
	5,150,706	09/1992	Cox et al.			
	5,186,711	02/1993	Epstein			
	5,192,314	03/1993	Dastolakis			
	5,256,132	10/1993	Snyders			
	5,290,217	03/1994	Campos			
	5,356,432	10/1994	Runkow et al.			
	5,383,840	01/1995	Heilman et al.			
NV	5,385,156	01/1995	Olivia			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
NV	WO 98/29041	07/1998	PCT				
	WO 98/58598	12/1998	PCT				
	WO 99/44534	09/1999	PCT				
NV	WO 00/02500	01/2000	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
NV		Coletta, C. et al., "Prognostic value of left ventricular volume response during dobutamine stress echocardiography", <i>European Heart Journal</i> , Vol. 18, pp. 1599-1605 (October 1997).
		Quera, P., "Una Prótesis contintiva para el tratamiento de la miocardiopatía dilatada", <i>Revista Española de Cardiología</i> , Vol. 51, No. 7, pp. 521-528 (July 1998).
		Kass, D. et al., "Reverse Remodeling From Cardiomyoplasty in Human Heart Failure External Constraint Versus Active Assist", <i>Circulation</i> , Vol. 91, No. 9, pp. 2314-2318 (May 1, 1995).
NV		Levin, H. et al., Reversal of Chronic Ventricular Dilation in Patients With End-Stage Cardiomyopathy by Prolonged Mechanical Unloading", <i>Circulation</i> , Vol. 91, No. 11, pp. 2717-2720 (June 1, 1995).

EXAMINER 	DATE CONSIDERED 07/16/05
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Date Mailed: November 17, 2003

Sheet 3 of 4

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11998.21USC2	Application Number: NEW FILING
	Applicant: ALFERNES ET AL.	
	Filing Date: HEREWITH	Group Art Unit: UNKNOWN

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
NV	5,429,584	07/1995	Chiu			
	5,507,779	04/1996	Alfarnes			
	5,524,633	06/1996	Heaven et al.			
	5,603,337	02/1997	Jarvik			
	5,647,380	07/1997	Campbell et al.			
	5,702,343	12/1997	Alfarnes			
	5,713,954	02/1998	Rosenberg et al.			
	5,800,528	09/1998	Lederman et al.			
	5,961,440	10/1999	Schweick, Jr. et al.			
	5,990,378	11/1999	Ellis			
NV	6,045,497	04/2000	Schweick, Jr. et al.			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
NV	WO 00/06026	02/2000	PCT				
	WO 00/06027	02/2000	PCT				
	WO 00/06028	02/2000	PCT				
NV	WO 00/16700	03/2000	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
NV	Oh, Jr. et al., "The Effects of Prosthetic Cardiac Binding and Adynamic Cardiomyoplasty in A Model Of Dilated Cardiomyopathy", <i>The Journal of Thoracic and Cardiovascular Surgery</i> , Vol. 116, No. 1, pp. 148-153 (July 1998).
	Paling, D., "Warp Knitting Technology", <i>Columbine Press</i> , p. 111 (1965).
NV	Vaynsblat, M. et al., "Cardiac Binding in Experimental Heart Failure", <i>Ann. Thorac. Surg.</i> , Vol. 64, 11 pages, (1997).

EXAMINER	DATE CONSIDERED 07/16/04
EXAMINER: Initials if reference considered, whether or not citation is in conformance with MPEP 909; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Date Mailed: November 17, 2003

Sheet 1 of 4

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11998.21USC2	Application Number: NEW FILING
	Applicant: ALFERNES ET AL.	
	Filing Date: HEREWITH	Group Art Unit: UNKNOWN

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	3,983,863	10/1976	Janku et al.			
	4,048,990	09/1977	Groetz			
	4,428,375	01/1984	Ellman			
	4,630,597	12/1986	Kantrowitz et al.			
	4,690,134	09/1987	Snyders			
	4,821,723	04/1989	Baker, Jr. et al.			
	4,878,890	11/1989	Bilweis			
	4,936,857	06/1990	Kulik			
	4,957,477	09/1990	Lundback			
	4,973,300	11/1990	Wright			
	4,976,730	12/1990	Kwan-Gert			
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	295 17 393 U 1	03/1996	DE			x
	0 280 564 A2	08/1988	EP			
	60-203250 A2	10/1985	JP			x
	01-145066 A	06/1989	JP			Abstract
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
		"Supplement to Circulation", <i>Abstracts from the 68th Scientific Sessions</i> , Vol. 92, No. 8, 2 pages (October 15, 1995) (Abstract No. 1810).				
		Capomolla, S. et al., "Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: Hemodynamic improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function", <i>American Heart Journal</i> , pp. 1089-1098 (December 1997).				
		Capouya, E. et al., "Girdling Effect of Nonstimulated Cardiomyoplasty on Left Ventricular Function", <i>Ann. Thorac Surg.</i> , Vol. 56, pp. 867-871 (1993).				
		Cohn, J., "The Management of Chronic Heart Failure", <i>The New England Journal of Medicine</i> , Vol. 335, No. 7, pp. 490-498 (August 15, 1996).				

34379

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE